The use of a DNA vaccine encoding the BCR/ABL fusion gene is thought to be a promising approach for patients with chronic myeloid leukemia (CML) to eradicate minimal residual disease after treatment with chemotherapy or targeted therapy. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.